A protein that makes skin cancer cells more invasive

November 20, 2018

Loss of a protein called TRIM29 promotes cancer cell invasion in a common type of skin cancer, suggesting a novel diagnostic marker and a possible therapeutic target.

Squamous cell carcinoma is a common type of skin cancer, usually affecting skin that is exposed to the damaging ultraviolet rays of the sun. A protein that normally helps repair DNA, called TRIM29, is also involved in cancers of the breast, pancreas, prostate, lungs, bladder and stomach. Its role in squamous cell carcinoma, however, was unknown until now.

A research team led by dermatologist Teruki Yanagi and Professor Shigetsugu Hatakeyama at Hokkaido University found that human squamous carcinoma cells with lower levels of TRIM29 were more mobile and invasive, and thus correlated with a worse prognosis. This study was published in Cancer Research.

TRIM29 expression was highest in normal skin cells. It was lower in squamous cell carcinomas, and even lower in tumors that metastasized, migrating from the main cancer site to other parts of the body, such as the lungs. The researchers also determined that turning off the gene made the cancer cells more mobile and invasive, both in cell cultures and mice.

Interestingly, they found that TRIM29 interacts with another protein inside cells called keratin, which plays numerous roles in forming a protective structural framework within cells and also in cell motility and signalling.

When TRIM29 levels are normal in a cell, it makes sure keratin is widely distributed within the cytoplasm. On the other hand, when TRIM29 levels are low, keratin distributes mainly around the cell nucleus, resulting in altered cell shapes.

Previous studies had shown that TRIM29 suppressed breast and prostate cancer development, because the protein is spread throughout the cytoplasm in these types of cells. But it promoted development of pancreatic, lung, bladder and stomach cancers, where it is localized in the nucleus. In skin cells, TRIM29 is normally positioned throughout the cytoplasm, reinforcing its protective role in suppressing skin cancer.

"Our findings suggest that TRIM29 could be a novel diagnostic and prognostic marker in squamous cell cancers common in skin, neck and head. The TRIM-29/keratin interaction could also be a therapeutic target for treating advanced and metastatic squamous cell cancers," says Teruki Yanagi.
-end-


Hokkaido University

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.